96 results on '"De Seigneux S"'
Search Results
2. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology
- Author
-
Zanchi, A., Jehle, A.W., Lamine, F., Vogt, B., Czerlau, C., Bilz, S., Seeger, H., and de Seigneux, S.
- Subjects
Humans ,Diabetic Nephropathies/therapy ,Diabetes Mellitus, Type 2/complications ,Diabetes Mellitus, Type 2/drug therapy ,Nephrology ,Blood Glucose/metabolism ,Switzerland ,Disease Progression ,Cardiovascular Diseases/etiology ,Renal Insufficiency, Chronic/complications ,610 Medicine & health ,General Medicine ,610 Medizin und Gesundheit - Abstract
Diabetic kidney disease is highly prevalent in patients with type 2 diabetes and is a major cause of end-stage renal disease in Switzerland. Patients with diabetic kidney disease are among the most complex patients in diabetes care. They require a multifactorial and multidisciplinary approach with the goal to slow the decline in glomerular filtration rate (GFR) and cardiovascular morbidity. With this consensus we propose an evidence-based guidance to health care providers involved in the care of type 2 diabetic patients with diabetic kidney disease. First, there is a need to increase physician awareness and improve screening for diabetic kidney disease as early intervention may improve clinical outcomes and the financial burden. Evaluation of estimated GFR (eGFR) and spot urine albumin/creatinine ratio is recommended at least annually. Once it is diagnosed, glucose control and optimisation of blood pressure control with renin-angiotensin system blockers have been recommended as mainstay management of diabetic kidney disease for more than 20 years. Recent, high quality randomised controlled trials have shown that sodium-glucose cotransporter-2 (SGLT2) inhibition slows eGFR decline and cardiovascular events beyond glucose control. Likewise, mineralocorticoid receptor antagonism with finerenone has cardiorenal protective effects in diabetic kidney disease. Glucagon-like peptide-1 (GLP1) receptor agonists improve weight loss if needed, and decrease albuminuria and cardiovascular morbidity. Lipid control is also important to decrease cardiovascular events. All these therapies are included in the treatment algorithms proposed in this consensus. With advancing kidney failure, other challenges may rise, such as hyperkalaemia, anaemia and metabolic acidosis, as well as chronic kidney disease-mineral and bone disorder. These different topics and treatment strategies are discussed in this consensus. Finally, an update on diabetes management in renal replacement therapy such as haemodialysis, peritoneal dialysis and renal transplantation is provided. With the recent developments of efficient therapies for diabetic kidney disease, it has become evident that a consensus document is necessary. We are optimistic that it will significantly contribute to a high-quality care for patients with diabetic kidney disease in Switzerland in the future.
- Published
- 2023
3. Inhibiteurs du SGLT2 dans les néphropathies diabétiques et non diabétiques [SGLT2 inhibitors in diabetic and non-diabetic nephropathies]
- Author
-
Scheen, M., Zanchi, A., Martin, P.Y., and De Seigneux, S.
- Subjects
Diabetes Mellitus, Type 2 ,Diabetic Nephropathies/drug therapy ,Humans ,Hypoglycemic Agents/therapeutic use ,Sodium-Glucose Transporter 2 ,Sodium-Glucose Transporter 2 Inhibitors/therapeutic use - Abstract
SGLT2 inhibitors (SGLT2i) will change the clinical practice of nephrology with their therapeutic cardiorenal and antidiabetic properties. By inhibiting proximal tubular sodium and glucose reabsorption, these new drugs decrease intraglomerular pressures. Over the last 5 years several breakthrough studies have demonstrated the SGLT2i protective effects on outcomes such as cardiovascular mortality, hospital admission for heart failure, sustained decreases in eGFR in patients with diabetic nephropathy and the development of ESKD. With the new DAPA-CKD study revealing protective effects of SGLT2i in CKD patients without diabetes, therapeutic recommendations will now have to evolve towards including these drugs in the chronic management of all most proteinuric CKD patients.
- Published
- 2021
4. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure
- Author
-
Saudan, P, Niederberger, M, De Seigneux, S, Romand, J, Pugin, J, Perneger, T, and Martin, P Y
- Published
- 2006
5. New Magnetic Resonance Imaging Index for Renal Fibrosis Assessment: A Comparison between Diffusion-Weighted Imaging and T1 Mapping with Histological Validation
- Author
-
Friedli, I., primary, Crowe, L. A., additional, Berchtold, L., additional, Moll, S., additional, Hadaya, K., additional, de Perrot, T., additional, Vesin, C., additional, Martin, P.-Y., additional, de Seigneux, S., additional, and Vallée, J.-P., additional
- Published
- 2016
- Full Text
- View/download PDF
6. Management of patients with nephrotic syndrome
- Author
-
de Seigneux, S. and Martin, Pierre-Yves
- Subjects
ddc:616 ,Dyslipidemias/etiology ,Angiotensin II Type 1 Receptor Blockers/*therapeutic use ,Angiotensin-Converting Enzyme Inhibitors/*therapeutic use ,Humans ,Hypertension/drug therapy/etiology ,Nephrotic Syndrome/complications/diagnosis/*drug therapy ,Anemia/etiology ,Thromboembolism/etiology ,Edema/etiology - Abstract
Nephrotic syndrome is characterised by proteinuria >3.5 g/24h, oedema, hypoalbuminaemia and hyperlipidaemia. Several glomerular diseases, either primary or secondary, may lead to nephrotic syndrome. Investigations for nephrotic syndrome include immunological and infectious evaluations. Renal biopsy is often mandatory, except in diabetes. Depending on aetiology specific treatment, often with immunosuppressive agents, may be implemented. In any cases nonspecific treatment should be started with ACE inhibitors or ARBs. Urinary protein loss leads to several complications: water and sodium retention, hyperlipidaemia, increased risk of thromboembolism and infection, anaemia and alteration of mineral metabolism. Each of these complications must be identified.
- Published
- 2009
7. Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 21! i beta-hydroxysteroid
- Author
-
Kim, S.W., Schou, U.K., Peters, C.D., de Seigneux, S., Kwon, Tae-Hwan, Knepper, Mark A., Jonassen, Thomas E.N., Frokiaer, J., Nielsen, S., Kim, S.W., Schou, U.K., Peters, C.D., de Seigneux, S., Kwon, Tae-Hwan, Knepper, Mark A., Jonassen, Thomas E.N., Frokiaer, J., and Nielsen, S.
- Published
- 2005
8. Rapid and segmental specific dysregulation of AQP2, S256-pAQP2 and renal sodium transporters in rats with LPS-induced endotoxaemia
- Author
-
Olesen, E. T. B., primary, de Seigneux, S., additional, Wang, G., additional, Lutken, S. C., additional, Frokiaer, J., additional, Kwon, T.-H., additional, and Nielsen, S., additional
- Published
- 2009
- Full Text
- View/download PDF
9. Extrarenale Entstehungsmechanismen von Ödemen
- Author
-
de Seigneux, S, primary, Feraille, E, additional, and Martin, PY, additional
- Published
- 2003
- Full Text
- View/download PDF
10. Mécanismes extrarénaux de la formation des oedèmes
- Author
-
de Seigneux, S, primary, Feraille, E, additional, and Martin, PY, additional
- Published
- 2003
- Full Text
- View/download PDF
11. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study
- Author
-
de Seigneux Sophie, Ponte Belen, Weiss Lucien, Pugin Jérôme, Romand Jacques, Martin Pierre-Yves, and Saudan Patrick
- Subjects
Erythropoetin ,NGAL ,Cytokines ,AKI ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background Experimentally, erythropoietin (EPO) has nephroprotective as well as immunomodulatory properties when administered after ischemic renal injury. We tested the hypothesis that different doses of recombinant human EPO administered to patients after cardiac surgery would minimize kidney lesions and the systemic inflammatory response, thereby decreasing acute kidney injury (AKI) incidence. Methods In this double-blinded randomized control study, 80 patients admitted to the ICU post-cardiac surgery were randomized by computer to receive intravenously isotonic saline (n = 40) versus α-Epoetin (n = 40): either 40000 IU (n = 20) or 20000 IU (n = 20). The study lasted one year. The primary outcome was the change in urinary NGAL concentration from baseline and 48 h after EPO injection. Creatinine, cystatine C and urinary NGAL levels were measured on the day of randomization and 2–4 days after EPO injection. To assess acute inflammatory response, serum cytokines (IL6 and IL8) were measured at randomization and four days after r-HuEPO injection. Patients and care-takers were blinded for the assignment. Results No patient was excluded after randomization. Patient groups did not differ in terms of age, gender, comorbidities and renal function at randomization. The rate of AKI assessed by AKIN criteria was 22.5% in our population. EPO treatment did not significantly modify the difference in uNGAl between 48 hours and randomization compared to placebo [2.5 ng/ml (−17.3; 22.5) vs 0.7 ng/ml (−31.77; 25.15), p = 0.77] and the incidence of AKI was similar. Inflammatory cytokines levels were not influenced by EPO treatment. Mortality and hospital stays were similar between the groups and no adverse event was recorded. Conclusion In this randomized-controlled trial, α-Epoetin administrated after cardiac surgery, although safe, demonstrated neither nephroprotective nor anti-inflammatory properties. Trial registration number NCT00676234
- Published
- 2012
- Full Text
- View/download PDF
12. Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: a prospective observational cohort study
- Author
-
Arlet Jean-Benoît, Ribeil Jean-Antoine, Chatellier Gilles, Eladari Dominique, De Seigneux Sophie, Souberbielle Jean-Claude, Friedlander Gérard, de Montalembert Marianne, Pouchot Jacques, Prié Dominique, and Courbebaisse Marie
- Subjects
Sickle cell disease ,Glomerular hyperfiltration ,Albuminuria ,Glomerular filtration rate ,CKD-EPI equation ,Iohexol plasma clearance ,Ethnicity ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background Sickle cell disease (SCD) leads to tissue hypoxia resulting in chronic organ dysfunction including SCD associated nephropathy. The goal of our study was to determine the best equation to estimate glomerular filtration rate (GFR) in SCD adult patients. Methods We conducted a prospective observational cohort study. Since 2007, all adult SCD patients in steady state, followed in two medical departments, have had their GFR measured using iohexol plasma clearance (gold standard). The Cockcroft-Gault, MDRD-v4, CKP-EPI and finally, MDRD and CKD-EPI equations without adjustment for ethnicity were tested to estimate GFR from serum creatinine. Estimated GFRs were compared to measured GFRs according to the graphical Bland and Altman method. Results Sixty-four SCD patients (16 men, median age 27.5 years [range 18.0-67.5], 41 with SS-genotype were studied. They were Sub-Saharan Africa and French West Indies natives and predominantly lean (median body mass index: 22 kg/m2 [16-33]). Hyperfiltration (defined as measured GFR >110 mL/min/1.73 m2) was detected in 53.1% of patients. Urinary albumin/creatinine ratio was higher in patients with hyperfiltration than in patients with normal GFR (4.05 mg/mmol [0.14-60] versus 0.4 mg/mmol [0.7-81], p = 0.01). The CKD-EPI equation without adjustment for ethnicity had both the lowest bias and the greatest precision. Differences between estimated GFRs using the CKP-EPI equation and measured GFRs decreased with increasing GFR values, whereas it increased with the Cockcroft-Gault and MDRD-v4 equations. Conclusions We confirm that SCD patients have a high rate of glomerular hyperfiltration, which is frequently associated with microalbuminuria or macroalbuminuria. In non-Afro-American SCD patients, the best method for estimating GFR from serum creatinine is the CKD-EPI equation without adjustment for ethnicity. This equation is particularly accurate to estimate high GFR values, including glomerular hyperfiltration, and thus should be recommended to screen SCD adult patients at high risk for SCD nephropathy.
- Published
- 2012
- Full Text
- View/download PDF
13. Oxalate nephropathy induced by octreotide treatment for acromegaly: a case report
- Author
-
Gariani Karim, de Seigneux Sophie, Courbebaisse Marie, Lévy Marc, Moll Solange, and Martin Pierre-Yves
- Subjects
Oxalate nephropathy ,Octreotide ,Antibiotics ,Oxalobacter formigenes ,Medicine - Abstract
Abstract Introduction Oxalate nephropathy has various etiologies and remains a rare cause of renal failure. To the best of our knowledge, we report the first case of oxalate nephropathy following octreotide therapy. Case presentation We report the case of a 78-year-old Caucasian man taking chronic octreotide treatment for acromegaly who presented with acute oxalate nephropathy after antibiotic therapy. The diagnosis was confirmed by urinary analysis and a kidney biopsy. The recovery of renal function was favorable after hydration and withdrawal of octreotide therapy. Conclusions Oxalate nephropathy should be suspected in patients at risk who present with acute kidney injury after prolonged antibiotic treatment. This diagnosis should be distinguished from immuno-allergic interstitial nephritis and requires specific care. The evolution of this condition may be favorable if the pathology is identified correctly. Octreotide therapy should be considered a risk factor for enteric oxaluria.
- Published
- 2012
- Full Text
- View/download PDF
14. Clinical prediction model for prognosis in kidney transplant recipients (KIDMO): study protocol
- Author
-
Schwab, Simon, Sidler, Daniel, Haidar, Fadi, Kuhn, Christian, Schaub, Stefan, Koller, Michael, Mellac, Katell, Stürzinger, Ueli, Tischhauser, Bruno, Binet, Isabelle, Golshayan, Déla, Müller, Thomas, Elmer, Andreas, Franscini, Nicola, Krügel, Nathalie, Fehr, Thomas, Immer, Franz, Swisstransplant Kidney Working Group (STAN), Swiss Transplant Cohort Study, Amico, P., Folie, P., Gannagé, M., Matter, M., Nilsson, J., Peloso, A., de Rougemont, O., Schnyder, A., Spartà, G., Storni, F., Villard, J., Wirth-Müller, U., Wolff, T., Aubert, J.D., Banz, V., Beckmann, S., Beldi, G., Berger, C., Berishvili, E., Berzigotti, A., Bochud, P.Y., Branca, S., Bucher, H., Catana, E., Cairoli, A., Chalandon, Y., De Geest, S., De Seigneux, S., Dickenmann, M., Dreifuss, J.L., Duchosal, M., Ferrari-Lacraz, S., Garzoni, C., Goossens, N., Halter, J., Heim, D., Hess, C., Hillinger, S., Hirsch, H.H., Hirt, P., Hoessly, L., Hofbauer, G., Huynh-Do, U., Laesser, B., Lamoth, F., Lehmann, R., Leichtle, A., Manuel, O., Marti, H.P., Martinelli, M., McLin, V., Merçay, A., Mettler, K., Mueller, N.J., Müller-Arndt, U., Müllhaupt, B., Nägeli, M., Oldani, G., Pascual, M., Passweg, J., Pazeller, R., Posfay-Barbe, K., Rick, J., Rosselet, A., Rossi, S., Rothlin, S., Ruschitzka, F., Schachtner, T., Scherrer, A., Schuurmans, M., Sengstag, T., Simonetta, F., Stampf, S., Steiger, J., Stirnimann, G., Van Delden, C., Venetz, J.P., Vionnet, J., Wick, M., Wilhelm, M., and Yerly, P.
- Subjects
Microbiology (medical) ,Immunology ,Immunology and Allergy ,610 Medicine & health ,Estimated glomerular filtration rate ,Graft survival ,Kidney transplantation ,Patient-reported health status ,Prediction model ,Prognosis ,Prognostic model ,Quality of life ,Risk calculator ,Risk score ,eGFR ,610 Medizin und Gesundheit - Abstract
Background Many potential prognostic factors for predicting kidney transplantation outcomes have been identified. However, in Switzerland, no widely accepted prognostic model or risk score for transplantation outcomes is being routinely used in clinical practice yet. We aim to develop three prediction models for the prognosis of graft survival, quality of life, and graft function following transplantation in Switzerland. Methods The clinical kidney prediction models (KIDMO) are developed with data from a national multi-center cohort study (Swiss Transplant Cohort Study; STCS) and the Swiss Organ Allocation System (SOAS). The primary outcome is the kidney graft survival (with death of recipient as competing risk); the secondary outcomes are the quality of life (patient-reported health status) at 12 months and estimated glomerular filtration rate (eGFR) slope. Organ donor, transplantation, and recipient-related clinical information will be used as predictors at the time of organ allocation. We will use a Fine & Gray subdistribution model and linear mixed-effects models for the primary and the two secondary outcomes, respectively. Model optimism, calibration, discrimination, and heterogeneity between transplant centres will be assessed using bootstrapping, internal-external cross-validation, and methods from meta-analysis. Discussion Thorough evaluation of the existing risk scores for the kidney graft survival or patient-reported outcomes has been lacking in the Swiss transplant setting. In order to be useful in clinical practice, a prognostic score needs to be valid, reliable, clinically relevant, and preferably integrated into the decision-making process to improve long-term patient outcomes and support informed decisions for clinicians and their patients. The state-of-the-art methodology by taking into account competing risks and variable selection using expert knowledge is applied to data from a nationwide prospective multi-center cohort study. Ideally, healthcare providers together with patients can predetermine the risk they are willing to accept from a deceased-donor kidney, with graft survival, quality of life, and graft function estimates available for their consideration. Study registration Open Science Framework ID: z6mvj
- Published
- 2023
15. Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients
- Author
-
Katharina, Kusejko, Frédérique, Chammartin, Daniel, Smith, Marc, Odermatt, Julian, Schuhmacher, Michael, Koller, Huldrych F, Günthard, Matthias, Briel, Heiner C, Bucher, Benjamin, Speich, Patrick, Yerly, Swiss HIV Cohort Study, Swiss Transplant Cohort Study, Abela, I., Aebi-Popp, K., Anagnostopoulos, A., Battegay, M., Bernasconi, E., Braun, D.L., Bucher, H.C., Calmy, A., Cavassini, M., Ciuffi, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, C.A., Günthard, H.F., Hachfeld, A., Haerry, D., Hasse, B., Hirsch, H.H., Hoffmann, M., Hösli, I., Huber, M., Kahlert, C.R., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, R.D., Kovari, H., Kusejko, K., Martinetti, G., Martinez de Tejada, B., Marzolini, C., Metzner, K.J., Müller, N., Nemeth, J., Nicca, D., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Wandeler, G., Yerly, S., Amico, P., Aubert, J.D., Banz, V., Beckmann, S., Beldi, G., Berger, C., Berishvili, E., Berzigotti, A., Binet, I., Bochud, P.Y., Branca, S., Bucher, H., Catana, E., Cairoli, A., Chalandon, Y., De Geest, S., De Rougemont, O., De Seigneux, S., Dickenmann, M., Dreifuss, J.L., Duchosal, M., Fehr, T., Ferrari-Lacraz, S., Garzoni, C., Golshayan, D., Goossens, N., Halter, FHJ, Heim, D., Hess, C., Hillinger, S., Hirt, P., Hofbauer, G., Huynh-Do, U., Immer, F., Koller, M., Laager, M., Laesser, B., Lamoth, F., Lehmann, R., Leichtle, A., Manuel, O., Marti, H.P., Martinelli, M., McLin, V., Mellac, K., Merçay, A., Mettler, K., Müller, A., Mueller, N.J., Müller-Arndt, U., Müllhaupt, B., Nägeli, M., Oldani, G., Pascual, M., Passweg, J., Pazeller, R., Posfay-Barbe, K., Rick, J., Rosselet, A., Rossi, S., Rothlin, S., Ruschitzka, F., Schachtner, T., Schanz, U., Schaub, S., Scherrer, A., Schnyder, A., Schuurmans, M., Schwab, S., Sengstag, T., Simonetta, F., Stampf, S., Steiger, J., Stirnimann, G., Stürzinger, U., Van Delden, C., Venetz, J.P., Villard, J., Vionnet, J., Wick, M., Wilhelm, M., Yerly, P., University of Zurich, and Kusejko, Katharina
- Subjects
10028 Institute of Medical Virology ,COVID-19 Vaccines ,SARS-CoV-2 ,COVID-19 ,610 Medicine & health ,2725 Infectious Diseases ,10234 Clinic for Infectious Diseases ,Cohort Studies ,Immunocompromised Host ,Treatment Outcome ,10032 Clinic for Oncology and Hematology ,10209 Clinic for Cardiology ,Humans ,10178 Clinic for Pneumology ,COVID-19/prevention & control ,HIV ,Immunocompromised ,REDCap ,Transplant patients ,Trial platform - Abstract
BACKGROUND The rapid course of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic calls for fast implementation of clinical trials to assess the effects of new treatment and prophylactic interventions. Building trial platforms embedded in existing data infrastructures is an ideal way to address such questions within well-defined subpopulations. METHODS We developed a trial platform building on the infrastructure of two established national cohort studies: the Swiss human immunodeficiency virus (HIV) Cohort Study (SHCS) and Swiss Transplant Cohort Study (STCS). In a pilot trial, termed Corona VaccinE tRiAL pLatform (COVERALL), we assessed the vaccine efficacy of the first two licensed SARS-CoV-2 vaccines in Switzerland and the functionality of the trial platform. RESULTS Using Research Electronic Data Capture (REDCap), we developed a trial platform integrating the infrastructure of the SHCS and STCS. An algorithm identifying eligible patients, as well as baseline data transfer ensured a fast inclusion procedure for eligible patients. We implemented convenient re-directions between the different data entry systems to ensure intuitive data entry for the participating study personnel. The trial platform, including a randomization algorithm ensuring balance among different subgroups, was continuously adapted to changing guidelines concerning vaccination policies. We were able to randomize and vaccinate the first trial participant the same day we received ethics approval. Time to enroll and randomize our target sample size of 380 patients was 22 days. CONCLUSION Taking the best of each system, we were able to flag eligible patients, transfer patient information automatically, randomize and enroll the patients in an easy workflow, decreasing the administrative burden usually associated with a trial of this size.
- Published
- 2022
16. Surgical site infections after simultaneous pancreas kidney and pancreas transplantation in the Swiss Transplant Cohort Study
- Author
-
P.W. Schreiber, M. Laager, K. Boggian, D. Neofytos, C. van Delden, A. Egli, M. Dickenmann, C. Hirzel, O. Manuel, M. Koller, S. Rossi, B. Schmied, L. Gürke, M. Matter, T. Berney, O. de Rougemont, S.P. Kuster, S. Stampf, N.J. Mueller, P. Amico, J-D. Aubert, V. Banz, S. Beckmann, G. Beldi, C. Berger, E. Berishvili, A. Berzigotti, I. Binet, P-Y. Bochud, S. Branca, H. Bucher, E. Catana, A. Cairoli, Y. Chalandon, S. De Geest, O. De Rougemont, S. De Seigneux, J.L. Dreifuss, M. Duchosal, T. Fehr, S. Ferrari-Lacraz, C. Garzoni, D. Golshayan, N. Goossens, F.H.J. Halter, D. Heim, C. Hess, S. Hillinger, H.H. Hirsch, P. Hirt, G. Hofbauer, U. Huynh-Do, F. Immer, B. Laesser, F. Lamoth, R. Lehmann, A. Leichtle, H.P. Marti, M. Martinelli, V. McLin, K. Mellac, A. Merçay, K. Mettler, A. Müller, U. Müller-Arndt, B. Müllhaupt, M. Nägeli, G. Oldani, M. Pascual, J. Passweg, R. Pazeller, K. Posfay-Barbe, J. Rick, A. Rosselet, S. Rothlin, F. Ruschitzka, T. Schachtner, U. Schanz, S. Schaub, A. Scherrer, A. Schnyder, M. Schuurmans, S. Schwab, T. Sengstag, F. Simonetta, J. Steiger, G. Stirnimann, U. Stürzinger, C. Van Delden, J-P. Venetz, J. Villard, J. Vionnet, M. Wick, M. Wilhelm, P. Yerly, Swiss Transplant Cohort Study, Amico, P., Aubert, J.D., Banz, V., Beckmann, S., Beldi, G., Berger, C., Berishvili, E., Berzigotti, A., Binet, I., Bochud, P.Y., Branca, S., Bucher, H., Catana, E., Cairoli, A., Chalandon, Y., De Geest, S., De Rougemont, O., De Seigneux, S., Dickenmann, M., Dreifuss, J.L., Duchosal, M., Fehr, T., Ferrari-Lacraz, S., Garzoni, C., Golshayan, D., Goossens, N., Halter, FHJ, Heim, D., Hess, C., Hillinger, S., Hirsch, H.H., Hirt, P., Hofbauer, G., Huynh-Do, U., Immer, F., Koller, M., Laager, M., Laesser, B., Lamoth, F., Lehmann, R., Leichtle, A., Manuel, O., Marti, H.P., Martinelli, M., McLin, V., Mellac, K., Merçay, A., Mettler, K., Müller, A., Mueller, N.J., Müller-Arndt, U., Müllhaupt, B., Nägeli, M., Oldani, G., Pascual, M., Passweg, J., Pazeller, R., Posfay-Barbe, K., Rick, J., Rosselet, A., Rossi, S., Rothlin, S., Ruschitzka, F., Schachtner, T., Schanz, U., Schaub, S., Scherrer, A., Schnyder, A., Schuurmans, M., Schwab, S., Sengstag, T., Simonetta, F., Stampf, S., Steiger, J., Stirnimann, G., Stürzinger, U., Van Delden, C., Venetz, J.P., Villard, J., Vionnet, J., Wick, M., Wilhelm, M., and Yerly, P.
- Subjects
Microbiology (medical) ,Adult ,610 Medicine & health ,General Medicine ,Kidney ,Cohort Studies ,Humans ,Kidney Transplantation/adverse effects ,Pancreas ,Pancreas Transplantation/adverse effects ,Risk Factors ,Surgical Wound Infection/epidemiology ,Surgical Wound Infection/etiology ,Switzerland/epidemiology ,Hospital-acquired infection ,Pancreas transplantation ,Simultaneous kidney–pancreas transplantation ,Surgical site infection ,Kidney Transplantation ,Infectious Diseases ,Surgical Wound Infection ,Pancreas Transplantation ,Switzerland - Abstract
BACKGROUND Among hospital-acquired infections, surgical site infections (SSIs) are frequent. SSI in the early post-transplant course poses a relevant threat to transplant recipients. AIM To determine incidence, risk factors for SSI and its association with post-transplant outcomes and pancreas transplant (P-Tx) recipients. METHODS Adult simultaneous kidney-pancreas transplantation (SPK-T) and P-Tx recipients with a follow-up of at least 90 days were identified in the Swiss Transplant Cohort Study (STCS) dataset. Except for the categorization of SSIs according to Centers for Disease Control and Prevention (CDC) criteria, all other data were prospectively collected. Risk factors for SSI were investigated with logistic regression. A Weibull accelerated failure-time model was applied to address the impact of SSI on length of stay, correcting for transplant-related complications and delayed graft function. FINDINGS Of 130 transplant recipients, 108 SPK-Tx and 22 P-Tx, 18 (14%) individuals developed SSI within the first 90 days after transplantation. Deep incisional (seven, 38.9%) and organ/space infections (eight, 44.4%) predominated. In the majority of SSIs (11, 61.1%; two SSIs with simultaneous identification of fungal pathogens) bacteria were detected with Enterococcus spp. being most frequent. The median duration of hospitalization after transplantation was significantly longer in recipients with SSI (median: 26 days; interquartile range (IQR): 19-44) than in patients without SSI (median: 17 days; IQR: 12-25; P = 0.002). In multivariate analysis, SSI was significantly associated with increased length of stay and prolonged the duration of hospitalization by 36% (95% confidence interval: 4-79). CONCLUSION SSI after SPK-Tx and P-Tx occurred at a frequency of 14%. Among pathogens, Enterococcus spp. predominated. SSI was independently associated with a longer hospitalization after transplantation.
- Published
- 2022
- Full Text
- View/download PDF
17. Early Complications in Kidney Donors and Course of Health-related Quality of Life 12 mo After Donation: An Analysis of the Swiss Organ Living-Donor Health Registry.
- Author
-
Brügger C, Hunkeler Z, Diebold M, Krättli J, Geiger I, Wehmeier C, Wolff T, Vogt B, Storni F, Golshayan D, Zingg T, de Seigneux S, Haidar F, Binet I, Schnyder A, Hübel K, Müller T, Rössler F, Steiger J, and Hirt-Minkowski P
- Abstract
Background: Since 1998, the Swiss Organ Living-Donor Health Registry (SOL-DHR) has recorded peri- and postoperative complications of living kidney (LK) donors, as reported by all Swiss transplant centers and has collected follow-up data prospectively., Methods: We analyzed the early complications of 2379 consecutive individuals who donated a kidney between January 1998 and June 2022 and assessed their health-related quality of life (HRQoL) 1 y after donation., Results: In total, 447 early complications in 404/2379 LK donors (17.0%) were reported to the SOL-DHR. The frequency of donors with major complications (ie, Dindo-Clavien classification 3/4) was 2.4%. In total, 31 donors needed reoperation, and in 13/31 (42%), donors reoperation was necessary because of bleeding complications. Independent risk factors for major early complications were older donor age ( P = 0.005) and type of surgical approach (ie, the laparoscopic retroperitoneal compared with laparoscopic transabdominal surgery; P = 0.01), but not sex. We observed a U -shaped association of body mass index, where very low/high body mass indexes had higher odds of major early complications, without reaching statistical significance. Although HRQoL was affected by kidney donation, 96.5% of donors indicated that they would donate their kidney again. The only independent risk factor for low HRQoL based on mental health scores was worsening EB after living kidney donation ( P < 0.0001)., Conclusions: Overall, living kidney donation is a safe procedure, however, donor age and type of surgical approach affect the risk of complications. A decline in emotional bonding with the recipient after donation may worsen the quality of life of the donor., (Copyright © 2024 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
18. Acute Kidney Injury and Hair-Straightening Products.
- Author
-
Huber A, Deffert C, Moll S, de Seigneux S, and Berchtold L
- Published
- 2024
- Full Text
- View/download PDF
19. Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients.
- Author
-
Hammer N, Hoessly L, Haidar F, Hirzel C, de Seigneux S, van Delden C, Vogt B, Sidler D, and Neofytos D
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Adult, Aged, Kidney drug effects, Transplant Recipients, Valganciclovir administration & dosage, Valganciclovir therapeutic use, Kidney Transplantation adverse effects, Cytomegalovirus Infections prevention & control, Antiviral Agents administration & dosage, Antiviral Agents adverse effects
- Abstract
Valganciclovir (VGC) is administered as prophylaxis to kidney transplant recipients (KTR) CMV donor (D)+/recipient (R)- and CMV R+ after thymoglobulin-induction (R+/TG). Although VGC dose adjustments based on renal function are recommended, there is paucity of real-life data on VGC dosing and associations with clinical outcomes. This is a retrospective Swiss Transplant Cohort Study-embedded observational study, including all adult D+/R- and R+/TG KTR between 2010 and 2020, who received prophylaxis with VGC. The primary objective was to describe the proportion of inappropriately (under- or over-) dosed VGC week-entries. Secondary objectives included breakthrough clinically significant CMV infection (csCMVi) and potential associations between breakthrough-csCMVi and cytopenias with VGC dosing. Among 178 KTR, 131 (73.6%) patients had ≥2 week-entries for the longitudinal data of interest and were included in the outcome analysis, with 1,032 VGC dose week-entries. Overall, 460/1,032 (44.6%) were appropriately dosed, while 234/1,032 (22.7%) and 338/1,032 (32.8%) were under- and over-dosed, respectively. Nineteen (14.5%) patients had a breakthrough-csCMVi, without any associations identified with VCG dosing ( p = 0.44). Unlike other cytopenias, a significant association between VGC overdosing and lymphopenia (OR 5.27, 95% CI 1.71-16.22, p = 0.004) was shown. VGC prophylaxis in KTR is frequently inappropriately dosed, albeit without meaningful clinical associations, neither in terms of efficacy nor safety., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Hammer, Hoessly, Haidar, Hirzel, de Seigneux, van Delden, Vogt, Sidler and Neofytos.)
- Published
- 2024
- Full Text
- View/download PDF
20. A transfer learning framework to elucidate the clinical relevance of altered proximal tubule cell states in kidney disease.
- Author
-
Legouis D, Rinaldi A, Malpetti D, Arnoux G, Verissimo T, Faivre A, Mangili F, Rinaldi A, Ruinelli L, Pugin J, Moll S, Clivio L, Bolis M, de Seigneux S, Azzimonti L, and Cippà PE
- Abstract
The application of single-cell technologies in clinical nephrology remains elusive. We generated an atlas of transcriptionally defined cell types and cell states of human kidney disease by integrating single-cell signatures reported in the literature with newly generated signatures obtained from 5 patients with acute kidney injury. We used this information to develop kidney-specific cell-level information ExtractoR (K-CLIER), a transfer learning approach specifically tailored to evaluate the role of cell types/states on bulk RNAseq data. We validated the K-CLIER as a reliable computational framework to obtain a dimensionality reduction and to link clinical data with single-cell signatures. By applying K-CLIER on cohorts of patients with different kidney diseases, we identified the most relevant cell types associated with fibrosis and disease progression. This analysis highlighted the central role of altered proximal tubule cells in chronic kidney disease. Our study introduces a new strategy to exploit the power of single-cell technologies toward clinical applications., Competing Interests: The authors declare no competing interests., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
21. Short-term hypercaloric carbohydrate loading increases surgical stress resilience by inducing FGF21.
- Author
-
Agius T, Emsley R, Lyon A, MacArthur MR, Kiesworo K, Faivre A, Stavart L, Lambelet M, Legouis D, de Seigneux S, Golshayan D, Lazeyras F, Yeh H, Markmann JF, Uygun K, Ocampo A, Mitchell SJ, Allagnat F, Déglise S, and Longchamp A
- Subjects
- Animals, Female, Humans, Male, Mice, Dietary Carbohydrates metabolism, Dietary Proteins metabolism, Liver surgery, Liver metabolism, Mice, Inbred C57BL, Diet, Carbohydrate Loading, Fibroblast Growth Factors metabolism, Reperfusion Injury metabolism, Surgical Procedures, Operative
- Abstract
Dietary restriction promotes resistance to surgical stress in multiple organisms. Counterintuitively, current medical protocols recommend short-term carbohydrate-rich drinks (carbohydrate loading) prior to surgery, part of a multimodal perioperative care pathway designed to enhance surgical recovery. Despite widespread clinical use, preclinical and mechanistic studies on carbohydrate loading in surgical contexts are lacking. Here we demonstrate in ad libitum-fed mice that liquid carbohydrate loading for one week drives reductions in solid food intake, while nearly doubling total caloric intake. Similarly, in humans, simple carbohydrate intake is inversely correlated with dietary protein intake. Carbohydrate loading-induced protein dilution increases expression of hepatic fibroblast growth factor 21 (FGF21) independent of caloric intake, resulting in protection in two models of surgical stress: renal and hepatic ischemia-reperfusion injury. The protection is consistent across male, female, and aged mice. In vivo, amino acid add-back or genetic FGF21 deletion blocks carbohydrate loading-mediated protection from ischemia-reperfusion injury. Finally, carbohydrate loading induction of FGF21 is associated with the induction of the canonical integrated stress response (ATF3/4, NF-kB), and oxidative metabolism (PPARγ). Together, these data support carbohydrate loading drinks prior to surgery and reveal an essential role of protein dilution via FGF21., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. Evolution of hypoxia and hypoxia-inducible factor asparaginyl hydroxylase regulation in chronic kidney disease.
- Author
-
Faivre A, Dissard R, Kuo W, Verissimo T, Legouis D, Arnoux G, Heckenmeyer C, Fernandez M, Tihy M, Rajaram RD, Delitsikou V, Le NA, Spingler B, Mueller B, Shulz G, Lindenmeyer M, Cohen C, Rutkowski JM, Moll S, Scholz CC, Kurtcuoglu V, and de Seigneux S
- Subjects
- Humans, Animals, Mice, X-Ray Microtomography, Repressor Proteins genetics, Down-Regulation, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Mixed Function Oxygenases genetics, Mixed Function Oxygenases metabolism, Hypoxia
- Abstract
Background: The roles of hypoxia and hypoxia inducible factor (HIF) during chronic kidney disease (CKD) are much debated. Interventional studies with HIF-α activation in rodents have yielded contradictory results. The HIF pathway is regulated by prolyl and asparaginyl hydroxylases. While prolyl hydroxylase inhibition is a well-known method to stabilize HIF-α, little is known about the effect asparaginyl hydroxylase factor inhibiting HIF (FIH)., Methods: We used a model of progressive proteinuric CKD and a model of obstructive nephropathy with unilateral fibrosis. In these models we assessed hypoxia with pimonidazole and vascularization with three-dimensional micro-computed tomography imaging. We analysed a database of 217 CKD biopsies from stage 1 to 5 and we randomly collected 15 CKD biopsies of various severity degrees to assess FIH expression. Finally, we modulated FIH activity in vitro and in vivo using a pharmacologic approach to assess its relevance in CKD., Results: In our model of proteinuric CKD, we show that early CKD stages are not characterized by hypoxia or HIF activation. At late CKD stages, some areas of hypoxia are observed, but these are not colocalizing with fibrosis. In mice and in humans, we observed a downregulation of the HIF pathway, together with an increased FIH expression in CKD, according to its severity. Modulating FIH in vitro affects cellular metabolism, as described previously. In vivo, pharmacologic FIH inhibition increases the glomerular filtration rate of control and CKD animals and is associated with decreased development of fibrosis., Conclusions: The causative role of hypoxia and HIF activation in CKD progression is questioned. A pharmacological approach of FIH downregulation seems promising in proteinuric kidney disease., (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2023
- Full Text
- View/download PDF
23. Calcification Propensity (T50) Predicts a Rapid Decline of Renal Function in Kidney Transplant Recipients.
- Author
-
Hammer N, Legouis D, Pasch A, Huber A, Al-Qusairi L, Martin PY, de Seigneux S, and Berchtold L
- Abstract
Background: Serum creatinine level, proteinuria, and interstitial fibrosis are predictive of renal prognosis. Fractional excretion of phosphate (FEP)/FGF23 ratio, tubular reabsorption of phosphate (TRP), serum calcification propensity (T50), and Klotho's serum level are emerging as determinants of poor kidney outcomes in CKD patients. We aimed at analysing the use of FGF23, FEP/FGF23, TRP, T50, and Klotho in predicting the rapid decline of renal function in kidney allograft recipients., Methods: We included 103 kidney allograft recipients in a retrospective study with a prospective follow-up of 4 years. We analysed the predictive values of FGF23, FEP/FGF23, TRP, T50, and Klotho for a rapid decline of renal function defined as a drop of eGFR > 30%., Results: During a follow-up of 4 years, 23 patients displayed a rapid decline of renal function. Tertile of FGF23 ( p value = 0.17), FEP/FGF23 ( p value = 0.78), TRP ( p value = 0.62) and Klotho ( p value = 0.31) were not associated with an increased risk of rapid decline of renal function in kidney transplant recipients. The lower tertile of T50 was significantly associated with eGFR decline >30% with a hazard ratio of 3.86 ( p = 0.048) and remained significant in multivariable analysis., Conclusion: T50 showed a strong association with a rapid decline of renal function in kidney allograft patients. This study underlines its role as an independent biomarker of loss of kidney function. We found no association between other phosphocalcic markers, such as FGF23, FEP/FGF23, TRP and Klotho, with a rapid decline of renal function in kidney allograft recipients.
- Published
- 2023
- Full Text
- View/download PDF
24. PCK1 is a key regulator of metabolic and mitochondrial functions in renal tubular cells.
- Author
-
Verissimo T, Dalga D, Arnoux G, Sakhi I, Faivre A, Auwerx H, Bourgeois S, Paolucci D, Gex Q, Rutkowski JM, Legouis D, Wagner CA, Hall AM, and de Seigneux S
- Subjects
- Animals, Mice, Glucose metabolism, Lactates metabolism, Mitochondria metabolism, Phosphoenolpyruvate metabolism, Phosphoenolpyruvate Carboxykinase (GTP) genetics, Phosphoenolpyruvate Carboxykinase (GTP) metabolism, Acidosis metabolism, Kidney metabolism
- Abstract
Phosphoenolpyruvate carboxykinase 1 (PCK1 or PEPCK-C) is a cytosolic enzyme converting oxaloacetate to phosphoenolpyruvate, with a potential role in gluconeogenesis, ammoniagenesis, and cataplerosis in the liver. Kidney proximal tubule cells display high expression of this enzyme, whose importance is currently not well defined. We generated PCK1 kidney-specific knockout and knockin mice under the tubular cell-specific PAX8 promoter. We studied the effect of PCK1 deletion and overexpression at the renal level on tubular physiology under normal conditions and during metabolic acidosis and proteinuric renal disease. PCK1 deletion led to hyperchloremic metabolic acidosis characterized by reduced but not abolished ammoniagenesis. PCK1 deletion also resulted in glycosuria, lactaturia, and altered systemic glucose and lactate metabolism at baseline and during metabolic acidosis. Metabolic acidosis resulted in kidney injury in PCK1-deficient animals with decreased creatinine clearance and albuminuria. PCK1 further regulated energy production by the proximal tubule, and PCK1 deletion decreased ATP generation. In proteinuric chronic kidney disease, mitigation of PCK1 downregulation led to better renal function preservation. PCK1 is essential for kidney tubular cell acid-base control, mitochondrial function, and glucose/lactate homeostasis. Loss of PCK1 increases tubular injury during acidosis. Mitigating kidney tubular PCK1 downregulation during proteinuric renal disease improves renal function. NEW & NOTEWORTHY Phosphoenolpyruvate carboxykinase 1 (PCK1) is highly expressed in the proximal tubule. We show here that this enzyme is crucial for the maintenance of normal tubular physiology, lactate, and glucose homeostasis. PCK1 is a regulator of acid-base balance and ammoniagenesis. Preventing PCK1 downregulation during renal injury improves renal function, rendering it an important target during renal disease.
- Published
- 2023
- Full Text
- View/download PDF
25. NADPH oxidase 4 is dispensable for skin myofibroblast differentiation and wound healing.
- Author
-
Siedlar AM, Seredenina T, Faivre A, Cambet Y, Stasia MJ, André-Lévigne D, Bochaton-Piallat ML, Pittet-Cuénod B, de Seigneux S, Krause KH, Modarressi A, and Jaquet V
- Subjects
- Animals, Humans, Mice, Cell Differentiation, Fibroblasts metabolism, Fibrosis, NADPH Oxidase 4 genetics, NADPH Oxidase 4 metabolism, NADPH Oxidases metabolism, Reactive Oxygen Species metabolism, Transforming Growth Factor beta metabolism, Transforming Growth Factor beta1, Wound Healing, Hydrogen Peroxide metabolism, Myofibroblasts metabolism
- Abstract
Differentiation of fibroblasts to myofibroblasts is governed by the transforming growth factor beta (TGF-β) through a mechanism involving redox signaling and generation of reactive oxygen species (ROS). Myofibroblasts synthesize proteins of the extracellular matrix (ECM) and display a contractile phenotype. Myofibroblasts are predominant contributors of wound healing and several pathological states, including fibrotic diseases and cancer. Inhibition of the ROS-generating enzyme NADPH oxidase 4 (NOX4) has been proposed to mitigate fibroblast to myofibroblast differentiation and to offer a therapeutic option for the treatment of fibrotic diseases. In this study, we addressed the role of NOX4 in physiological wound healing and in TGF-β-induced myofibroblast differentiation. We explored the phenotypic changes induced by TGF-β in primary skin fibroblasts isolated from Nox4-deficient mice by immunofluorescence, Western blotting and RNA sequencing. Mice deficient for Cyba, the gene coding for p22
phox , a key subunit of NOX4 were used for confirmatory experiments as well as human primary skin fibroblasts. In vivo, the wound healing was similar in wild-type and Nox4-deficient mice. In vitro, despite a strong upregulation following TGF-β treatment, Nox4 did not influence skin myofibroblast differentiation although a putative NOX4 inhibitor GKT137831 and a flavoprotein inhibitor diphenylene iodonium mitigated this mechanism. Transcriptomic analysis revealed upregulation of the mitochondrial protein Ucp2 and the stress-response protein Hddc3 in Nox4-deficient fibroblasts, which had however no impact on fibroblast bioenergetics. Altogether, we provide extensive evidence that NOX4 is dispensable for wound healing and skin fibroblast to myofibroblast differentiation, and suggest that another H2 O2 -generating flavoprotein drives this mechanism., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
26. Gluconeogenesis in the kidney: in health and in chronic kidney disease.
- Author
-
Dalga D, Verissimo T, and de Seigneux S
- Abstract
Chronic kidney disease (CKD) is a global health issue with increasing prevalence. Despite large improvements in current therapies, slowing CKD progression remains a challenge. A better understanding of renal pathophysiology is needed to offer new therapeutic targets. The role of metabolism alterations and mitochondrial dysfunction in tubular cells is increasingly recognized in CKD progression. In proximal tubular cells, CKD progression is associated with a switch from fatty acid oxidation to glycolysis. Glucose synthesis through gluconeogenesis is one of the principal physiological functions of the kidney. Loss of tubular gluconeogenesis in a stage-dependent manner is a key feature of CKD and contributes to systemic and possibly local metabolic complications. The local consequences observed may be related to an accumulation of precursors, such as glycogen, but also to the various physiological functions of the gluconeogenesis enzymes. The basic features of metabolism in proximal tubular cells and their modifications during CKD will be reviewed. The metabolic modifications and their influence on kidney disease will be described, as well as the local and systemic consequences. Finally, therapeutic interventions will be discussed., Competing Interests: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2023
- Full Text
- View/download PDF
27. Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis.
- Author
-
Jaques DA, Ponte B, Haidar F, Dufey A, Carballo S, De Seigneux S, and Saudan P
- Subjects
- Adult, Humans, Renal Dialysis methods, Retrospective Studies, Renal Replacement Therapy, Kidney Failure, Chronic, Peritoneal Dialysis
- Abstract
Background: Residual kidney function is considered better preserved with incremental haemodialysis (I-HD) or peritoneal dialysis (PD) as compared with conventional thrice-weekly HD (TW-HD) and is associated with improved survival. We aimed to describe outcomes of patients initiating dialysis with I-HD, TW-HD or PD., Methods: We conducted a retrospective analysis of a prospectively assembled cohort in a single university centre including all adults initiating dialysis from January 2013 to December 2020. Primary and secondary endpoints were overall survival and hospitalization days at 1 year, respectively., Results: We included 313 patients with 234 starting on HD (166 TW-HD and 68 I-HD) and 79 on PD. At the end of the study, 10 were still on I-HD while 45 transitioned to TW-HD after a mean duration of 9.8 ± 9.1 months. Patients who stayed on I-HD were less frequently diabetics (P = .007). Mean follow-up was 33.1 ± 30.8 months during which 124 (39.6%) patients died. Compared with patients on TW-HD, those on I-HD had improved survival (hazard ratio 0.49, 95% confidence interval 0.26-0.93, P = .029), while those on PD had similar survival. Initial kidney replacement therapy modality was not significantly associated with hospitalization days at 1 year., Conclusions: I-HD is suitable for selected patients starting dialysis and can be maintained for a significant amount of time before transition to TW-HD, with diabetes being a risk factor. Although hospitalization days at 1 year are similar, initiation with I-HD is associated with improved survival as compared with TW-HD or PD. Results of randomized controlled trials are awaited prior to large-scale implementation of I-HD programmes., (© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2022
- Full Text
- View/download PDF
28. Glomerulocystic kidney disease.
- Author
-
Scheen M, Paoloni-Giacobino A, Nguyen-Tang EG, Vidal J, De Seigneux S, and Haidar F
- Subjects
- Humans, Kidney Diseases, Cystic, Kidney Diseases, Urinary Tract, Polycystic Kidney Diseases
- Published
- 2022
- Full Text
- View/download PDF
29. Kidney-targeted irradiation triggers renal ischemic preconditioning in mice.
- Author
-
Khbouz B, Lallemand F, Cirillo A, Rowart P, Legouis D, Sounni NE, Noël A, De Tullio P, de Seigneux S, and Jouret F
- Subjects
- Animals, Ischemia metabolism, Kidney metabolism, Male, Mice, Mice, Inbred C57BL, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Acute Kidney Injury etiology, Acute Kidney Injury pathology, Acute Kidney Injury prevention & control, Ischemic Preconditioning, Reperfusion Injury pathology
- Abstract
Renal ischemia-reperfusion (I/R) causes acute kidney injury (AKI). Ischemic preconditioning (IPC) attenuates I/R-associated AKI. Whole body irradiation induces renal IPC in mice. Still, the mechanisms remain largely unknown. Furthermore, the impact of kidney-centered irradiation on renal resistance against I/R has not been studied. Renal irradiation (8.5 Gy) was done in male 8- to 12-wk-old C57bl/6 mice using a small animal radiation therapy device. Left renal I/R was performed by clamping the renal pedicles for 30 min, with simultaneous right nephrectomy, at 7, 14, and 28 days postirradiation. The renal reperfusion lasted 48 h. Following I/R, blood urea nitrogen (BUN) and serum creatinine (SCr) levels were lower in preirradiated mice compared with controls; so was the histological Jablonski score of AKI. The metabolomics signature of renal I/R was attenuated in preirradiated mice. The numbers of proliferating cell nuclear antigen (PCNA)-, cluster of differentiation molecule 11b (CD11b)-, and cell surface glycoprotein F4/80-positive cells in the renal parenchyma post-I/R were reduced in preirradiated versus control groups. Such IPC was significantly observed as early as day 14 postirradiation. RNA sequencing showed an upregulation of angiogenesis- and stress response-related signaling pathways in irradiated nonischemic kidneys on day 28 . Qualitative RT-PCR confirmed the increased expression of vascular endothelial growth factor ( VEGF ), activin receptor-like kinase 5 ( ALK5 ), heme oxygenase-1 ( HO1 ), platelet endothelial cell adhesion molecule-1 ( PECAM1 ), NADPH oxidase 2 ( NOX2 ), and heat shock proteins 70 and 27 ( HSP70 and HSP27 , respectively) in irradiated kidneys compared with controls. In addition, irradiated kidneys showed an increased CD31-positive vascular area compared with controls. A 14-day gavage of irradiated mice with the antiangiogenic drug sunitinib before I/R abrogated the irradiation-induced IPC at both functional and structural levels. Our observations suggest that kidney-centered irradiation activates proangiogenic pathways and induces IPC, with preserved renal function and attenuated inflammation post-I/R. NEW & NOTEWORTHY This study based on a mouse model of renal ischemia-reperfusion (I/R) aimed to 1 ) test whether and how irradiation strictly centered on the kidney protects against the I/R injury and 2 ) determine the shortest efficient delay of kidney irradiation to achieve such nephroprotection. Kidney irradiation increased the vascular surface in the renal parenchyma and conferred resistance against renal I/R damage, which highlights novel putative strategies in the field of ischemic acute kidney injury.
- Published
- 2022
- Full Text
- View/download PDF
30. Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism.
- Author
-
Legouis D, Faivre A, Cippà PE, and de Seigneux S
- Subjects
- Glucose metabolism, Humans, Insulin metabolism, Lactates metabolism, Gluconeogenesis, Kidney metabolism
- Abstract
Glucose levels are tightly regulated at all times. Gluconeogenesis is the metabolic pathway dedicated to glucose synthesis from non-hexose precursors. Gluconeogenesis is critical for glucose homoeostasis, particularly during fasting or stress conditions. The renal contribution to systemic gluconeogenesis is increasingly recognized. During the post-absorptive phase, the kidney accounts for ∼40% of endogenous gluconeogenesis, occurring mainly in the kidney proximal tubule. The main substrate for renal gluconeogenesis is lactate and the process is regulated by insulin and cellular glucose levels, but also by acidosis and stress hormones. The kidney thus plays an important role in the maintenance of glucose and lactate homoeostasis during stress conditions. The impact of acute and chronic kidney disease and proximal tubular injury on gluconeogenesis is not well studied. Recent evidence shows that in both experimental and clinical acute kidney injury, impaired renal gluconeogenesis could significantly participate in systemic metabolic disturbance and thus alter the prognosis. This review summarizes the biochemistry of gluconeogenesis, the current knowledge of kidney gluconeogenesis, its modifications in kidney disease and the clinical relevance of this fundamental biological process in human biology., Competing Interests: None declared., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.)
- Published
- 2022
- Full Text
- View/download PDF
31. Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial.
- Author
-
Jaques DA, Stucker F, Ernandez T, Alves C, Martin PY, De Seigneux S, and Saudan P
- Abstract
Background: Hyperkalaemia is frequent in haemodialysis (HD) patients and associated with increased cardiovascular mortality. Despite routine clinical use, evidence regarding the efficacy of potassium (K
+ ) binders in HD is scant. We wished to compare the efficacy of patiromer (PAT) and sodium polystyrene sulfonate (SPS) on K+ levels in this setting., Methods: We screened patients in three HD centres with pre-HD K+ value between 5.0 and 6.4 mmol/L, after an initial 2-week washout period for those previously on K+ binders. We included patients in an unblinded two-arm crossover trial comparing SPS 15 g before each meal on non-dialysis days with PAT 16.8 g once daily on non-dialysis days with randomized attribution order and a 2-week intermediate washout period. The primary outcome was the mean weekly K+ value., Results: We included 51 patients and analysed 48 with mean age of 66.4 ± 19.4 years, 72.9% men and 43.4% diabetics. Mean weekly K+ values were 5.00 ± 0.54 mmol/L, 4.55 ± 0.75 mmol/L and 5.17 ± 0.64 mmol/L under PAT ( P = .003), SPS ( P < .001) and washout, respectively. In direct comparison, K+ values and prevalence of hyperkalaemia were lower under SPS as compared with PAT ( P < .001). While the incidence of gastrointestinal side effects was similar between treatments, SPS showed lower subjective tolerability score (6.0 ± 2.4 and 6.9 ± 1.9) and compliance (10.8 ± 20.4% and 2.4 ± 7.3% missed doses) as compared with PAT ( P < .001 for both)., Conclusion: Both PAT and SPS are effective in decreasing K+ levels in chronic HD patients. However, at the tested doses, SPS was significantly more effective in doing so as compared with PAT, despite lower tolerability and compliance. Larger randomized controlled trials should be conducted in order to confirm our findings and determine whether they would impact clinical outcomes., (© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.)- Published
- 2022
- Full Text
- View/download PDF
32. Decreased Renal Gluconeogenesis Is a Hallmark of Chronic Kidney Disease.
- Author
-
Verissimo T, Faivre A, Rinaldi A, Lindenmeyer M, Delitsikou V, Veyrat-Durebex C, Heckenmeyer C, Fernandez M, Berchtold L, Dalga D, Cohen C, Naesens M, Ricksten SE, Martin PY, Pugin J, Merlier F, Haupt K, Rutkowski JM, Moll S, Cippà PE, Legouis D, and de Seigneux S
- Subjects
- Animals, Humans, Kidney metabolism, Kidney Tubules, Proximal metabolism, Mice, Retrospective Studies, Gluconeogenesis physiology, Renal Insufficiency, Chronic metabolism
- Abstract
Introduction: CKD is associated with alterations of tubular function. Renal gluconeogenesis is responsible for 40% of systemic gluconeogenesis during fasting, but how and why CKD affects this process and the repercussions of such regulation are unknown., Methods: We used data on the renal gluconeogenic pathway from more than 200 renal biopsies performed on CKD patients and from 43 kidney allograft patients, and studied three mouse models, of proteinuric CKD (POD-ATTAC), of ischemic CKD, and of unilateral urinary tract obstruction. We analyzed a cohort of patients who benefitted from renal catheterization and a retrospective cohort of patients hospitalized in the intensive care unit., Results: Renal biopsies of CKD and kidney allograft patients revealed a stage-dependent decrease in the renal gluconeogenic pathway. Two animal models of CKD and one model of kidney fibrosis confirm gluconeogenic downregulation in injured proximal tubule cells. This shift resulted in an alteration of renal glucose production and lactate clearance during an exogenous lactate load. The isolated perfused kidney technique in animal models and renal venous catheterization in CKD patients confirmed decreased renal glucose production and lactate clearance. In CKD patients hospitalized in the intensive care unit, systemic alterations of glucose and lactate levels were more prevalent and associated with increased mortality and a worse renal prognosis at follow-up. Decreased expression of the gluconeogenesis pathway and its regulators predicted faster histologic progression of kidney disease in kidney allograft biopsies., Conclusion: Renal gluconeogenic function is impaired in CKD. Altered renal gluconeogenesis leads to systemic metabolic changes with a decrease in glucose and increase in lactate level, and is associated with a worse renal prognosis., (Copyright © 2022 by the American Society of Nephrology.)
- Published
- 2022
- Full Text
- View/download PDF
33. Diffusion-Weighted MRI in the Genitourinary System.
- Author
-
De Perrot T, Sadjo Zoua C, Glessgen CG, Botsikas D, Berchtold L, Salomir R, De Seigneux S, Thoeny HC, and Vallée JP
- Abstract
Diffusion weighted imaging (DWI) constitutes a major functional parameter performed in Magnetic Resonance Imaging (MRI). The DW sequence is performed by acquiring a set of native images described by their b-values, each b-value representing the strength of the diffusion MR gradients specific to that sequence. By fitting the data with models describing the motion of water in tissue, an apparent diffusion coefficient (ADC) map is built and allows the assessment of water mobility inside the tissue. The high cellularity of tumors restricts the water diffusion and decreases the value of ADC within tumors, which makes them appear hypointense on ADC maps. The role of this sequence now largely exceeds its first clinical apparitions in neuroimaging, whereby the method helped diagnose the early phases of cerebral ischemic stroke. The applications extend to whole-body imaging for both neoplastic and non-neoplastic diseases. This review emphasizes the integration of DWI in the genitourinary system imaging by outlining the sequence's usage in female pelvis, prostate, bladder, penis, testis and kidney MRI. In gynecologic imaging, DWI is an essential sequence for the characterization of cervix tumors and endometrial carcinomas, as well as to differentiate between leiomyosarcoma and benign leiomyoma of the uterus. In ovarian epithelial neoplasms, DWI provides key information for the characterization of solid components in heterogeneous complex ovarian masses. In prostate imaging, DWI became an essential part of multi-parametric Magnetic Resonance Imaging (mpMRI) to detect prostate cancer. The Prostate Imaging-Reporting and Data System (PI-RADS) scoring the probability of significant prostate tumors has significantly contributed to this success. Its contribution has established mpMRI as a mandatory examination for the planning of prostate biopsies and radical prostatectomy. Following a similar approach, DWI was included in multiparametric protocols for the bladder and the testis. In renal imaging, DWI is not able to robustly differentiate between malignant and benign renal tumors but may be helpful to characterize tumor subtypes, including clear-cell and non-clear-cell renal carcinomas or low-fat angiomyolipomas. One of the most promising developments of renal DWI is the estimation of renal fibrosis in chronic kidney disease (CKD) patients. In conclusion, DWI constitutes a major advancement in genitourinary imaging with a central role in decision algorithms in the female pelvis and prostate cancer, now allowing promising applications in renal imaging or in the bladder and testicular mpMRI.
- Published
- 2022
- Full Text
- View/download PDF
34. Anasarca, and Lymphadenopathy in a Kidney Transplant Patient: A Diagnostic and Therapeutic Challenge.
- Author
-
Huegli S, Jaques DA, De Seigneux S, and Haidar F
- Subjects
- Edema etiology, Humans, Kidney Transplantation adverse effects, Lymphadenopathy
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
35. Dietary sodium intake does not alter renal potassium handling and blood pressure in healthy young males.
- Author
-
Pechère-Bertschi A, Olivier V, Burnier M, Udwan K, de Seigneux S, Ponte B, Maillard M, Martin PY, and Feraille E
- Subjects
- Blood Pressure, Humans, Kidney Tubules, Distal, Male, Natriuresis, Potassium, Dietary pharmacology, Sodium, Sodium Chloride, Dietary, Potassium, Sodium, Dietary pharmacology
- Abstract
Background: The effects of sodium (Na+) intakes on renal handling of potassium (K+) are insufficiently studied., Methods: We assessed the effect of Na+ on renal K+ handling in 16 healthy males assigned to three 7-day periods on low salt diet [LSD, 3 g sodium chloride (NaCl)/day], normal salt diet (NSD, 6 g NaCl/day) and high salt diet (HSD, 15 g NaCl/day), with constant K+ intake. Contributions of distal NaCl co-transporter and epithelial Na+ channel in the collecting system on K+ and Na+ handling were assessed at steady state by acute response to 100 mg oral hydrochlorothiazide and with addition of 10 mg of amiloride to hydrochlorothiazide, respectively., Results: Diurnal blood pressure slightly increased from 119.30 ± 7.95 mmHg under LSD to 123.00 ± 7.50 mmHg (P = 0.02) under HSD, while estimated glomerular filtration rate increased from 133.20 ± 34.68 mL/min under LSD to 187.00 ± 49.10 under HSD (P = 0.005). The 24-h K+ excretion remained stable on all Na+ intakes (66.28 ± 19.12 mmol/24 h under LSD; 55.91 ± 21.17 mmol/24 h under NSD; and 66.81 ± 20.72 under HSD, P = 0.9). The hydrochlorothiazide-induced natriuresis was the highest under HSD (30.22 ± 12.53 mmol/h) and the lowest under LSD (15.38 ± 8.94 mmol/h, P = 0.02). Hydrochlorothiazide increased kaliuresis and amiloride decreased kaliuresis similarly on all three diets., Conclusions: Neither spontaneous nor diuretic-induced K+ excretion was influenced by Na+ intake in healthy male subjects. However, the respective contribution of the distal convoluted tubule and the collecting duct to renal Na+ handling was dependent on dietary Na+ intake., (© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2022
- Full Text
- View/download PDF
36. Haemoglobin as a marker of fibrosis in early diabetic kidney disease.
- Author
-
Faivre A and de Seigneux S
- Subjects
- Biomarkers, Fibrosis, Hemoglobin, Sickle, Hemoglobins, Humans, Diabetes Mellitus, Diabetic Nephropathies diagnosis, Diabetic Nephropathies etiology, Diabetic Nephropathies physiopathology
- Published
- 2022
- Full Text
- View/download PDF
37. Estimated Renal Metabolomics at Reperfusion Predicts One-Year Kidney Graft Function.
- Author
-
Verissimo T, Faivre A, Sgardello S, Naesens M, de Seigneux S, Criton G, and Legouis D
- Abstract
Renal transplantation is the gold-standard procedure for end-stage renal disease patients, improving quality of life and life expectancy. Despite continuous advancement in the management of post-transplant complications, progress is still needed to increase the graft lifespan. Early identification of patients at risk of rapid graft failure is critical to optimize their management and slow the progression of the disease. In 42 kidney grafts undergoing protocol biopsies at reperfusion, we estimated the renal metabolome from RNAseq data. The estimated metabolites' abundance was further used to predict the renal function within the first year of transplantation through a random forest machine learning algorithm. Using repeated K-fold cross-validation we first built and then tuned our model on a training dataset. The optimal model accurately predicted the one-year eGFR, with an out-of-bag root mean square root error (RMSE) that was 11.8 ± 7.2 mL/min/1.73 m
2 . The performance was similar in the test dataset, with a RMSE of 12.2 ± 3.2 mL/min/1.73 m2 . This model outperformed classic statistical models. Reperfusion renal metabolome may be used to predict renal function one year after allograft kidney recipients.- Published
- 2022
- Full Text
- View/download PDF
38. Tubular Cell Glucose Metabolism Shift During Acute and Chronic Injuries.
- Author
-
Faivre A, Verissimo T, Auwerx H, Legouis D, and de Seigneux S
- Abstract
Acute and chronic kidney disease are responsible for large healthcare costs worldwide. During injury, kidney metabolism undergoes profound modifications in order to adapt to oxygen and nutrient shortage. Several studies highlighted recently the importance of these metabolic adaptations in acute as well as in chronic phases of renal disease, with a potential deleterious effect on fibrosis progression. Until recently, glucose metabolism in the kidney has been poorly studied, even though the kidney has the capacity to use and produce glucose, depending on the segment of the nephron. During physiology, renal proximal tubular cells use the beta-oxidation of fatty acid to generate large amounts of energy, and can also produce glucose through gluconeogenesis. In acute kidney injury, proximal tubular cells metabolism undergo a metabolic shift, shifting away from beta-oxidation of fatty acids and gluconeogenesis toward glycolysis. In chronic kidney disease, the loss of fatty acid oxidation is also well-described, and data about glucose metabolism are emerging. We here review the modifications of proximal tubular cells glucose metabolism during acute and chronic kidney disease and their potential consequences, as well as the potential therapeutic implications., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Faivre, Verissimo, Auwerx, Legouis and de Seigneux.)
- Published
- 2021
- Full Text
- View/download PDF
39. Hypoxia in chronic kidney disease: towards a paradigm shift?
- Author
-
Faivre A, Scholz CC, and de Seigneux S
- Subjects
- Animals, Fibrosis, Hypoxia, Kidney, Mice, Anemia, Renal Insufficiency, Chronic etiology
- Abstract
Chronic kidney disease (CKD) is defined as an alteration of kidney structure and/or function lasting for >3 months [1]. CKD affects 10% of the general adult population and is responsible for large healthcare costs [2]. Since the end of the last century, the role of hypoxia in CKD progression has controversially been discussed. To date, there is evidence of the presence of hypoxia in late-stage renal disease, but we lack time-course evidence, stage correlation and also spatial co-localization with fibrotic lesions to ensure its causative role. The classical view of hypoxia in CKD progression is that it is caused by peritubular capillary alterations, renal anaemia and increased oxygen consumption regardless of the primary injury. In this classical view, hypoxia is assumed to further induce pro-fibrotic and pro-inflammatory responses, as well as oxidative stress, leading to CKD worsening as part of a vicious circle. However, recent investigations tend to question this paradigm, and both the presence of hypoxia and its role in CKD progression are still not clearly demonstrated. Hypoxia-inducible factor (HIF) is the main transcriptional regulator of the hypoxia response. Genetic HIF modulation leads to variable effects on CKD progression in different murine models. In contrast, pharmacological modulation of the HIF pathway [i.e. by HIF hydroxylase inhibitors (HIs)] appears to be generally protective against fibrosis progression experimentally. We here review the existing literature on the role of hypoxia, the HIF pathway and HIF HIs in CKD progression and summarize the evidence that supports or rejects the hypoxia hypothesis, respectively., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
40. Impact of Hyponatremia after Renal Transplantation on Decline of Renal Function, Graft Loss and Patient Survival: A Prospective Cohort Study.
- Author
-
Berchtold L, Filzer A, Achermann R, Devetzis V, Dahdal S, Bonani M, Schnyder A, Golshayan D, Amico P, Huynh-Do U, de Seigneux S, Arampatzis S, and On Behalf Of Swiss Transplant Cohort Study Collaborators
- Subjects
- Adult, Cohort Studies, Female, Graft Rejection physiopathology, Humans, Hyponatremia physiopathology, Kidney physiopathology, Male, Middle Aged, Prospective Studies, Survival Analysis, Switzerland, Graft Rejection complications, Hyponatremia complications, Kidney Transplantation, Transplant Recipients statistics & numerical data
- Abstract
Background: Hyponatremia is one of the most common electrolyte disorders observed in hospitalized and ambulatory patients. Hyponatremia is associated with increased falls, fractures, prolonged hospitalisation and mortality. The clinical importance of hyponatremia in the renal transplant field is not well established, so the aim of this study was to determine the relationships between hyponatremia and mortality as main outcome and renal function decline and graft loss as secondary outcome among a prospective cohort of renal transplant recipients., Methods: This prospective cohort study included 1315 patients between 1 May 2008 and 31 December 2014. Hyponatremia was defined as sodium concentration below 136 mmol/L at 6 months after transplantation. The main endpoint was mortality. A secondary composite endpoint was also defined as: rapid decline in renal function (≥5 mL/min/1.73 m
2 drop of the eGFR/year), graft loss or mortality., Results: Mean sodium was 140 ± 3.08 mmol/L. 97 patients displayed hyponatremia with a mean of 132.9 ± 3.05 mmol/L. Hyponatremia at 6 months after transplantation was associated neither with mortality (HR: 1.02; p = 0.97, 95% CI: 0.47-2.19), nor with the composite outcome defined as rapid decline in renal function, graft loss or mortality (logrank test p = 0.9)., Conclusions: Hyponatremia 6 months after transplantation is not associated with mortality in kidney allograft patients.- Published
- 2021
- Full Text
- View/download PDF
41. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
- Author
-
Faivre A, Katsyuba E, Verissimo T, Lindenmeyer M, Rajaram RD, Naesens M, Heckenmeyer C, Mottis A, Feraille E, Cippà P, Cohen C, Longchamp A, Allagnat F, Rutkowski JM, Legouis D, Auwerx J, and de Seigneux S
- Subjects
- Acute Kidney Injury chemically induced, Acute Kidney Injury drug therapy, Acute Kidney Injury metabolism, Animals, Antineoplastic Agents toxicity, Cisplatin toxicity, Disease Progression, Humans, Male, Mice, Mice, Inbred C57BL, Niacinamide administration & dosage, Niacinamide deficiency, Pyridinium Compounds, Renal Insufficiency, Chronic chemically induced, Renal Insufficiency, Chronic drug therapy, Renal Insufficiency, Chronic metabolism, Reperfusion Injury chemically induced, Reperfusion Injury drug therapy, Reperfusion Injury metabolism, Acute Kidney Injury pathology, Disease Models, Animal, Niacinamide analogs & derivatives, Renal Insufficiency, Chronic pathology, Reperfusion Injury pathology
- Abstract
Background: Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous coenzyme involved in electron transport and a co-substrate for sirtuin function. NAD+ deficiency has been demonstrated in the context of acute kidney injury (AKI)., Methods: We studied the expression of key NAD+ biosynthesis enzymes in kidney biopsies from human allograft patients and patients with chronic kidney disease (CKD) at different stages. We used ischaemia-reperfusion injury (IRI) and cisplatin injection to model AKI, urinary tract obstruction [unilateral ureteral obstruction (UUO)] and tubulointerstitial fibrosis induced by proteinuria to investigate CKD in mice. We assessed the effect of nicotinamide riboside (NR) supplementation on AKI and CKD in animal models., Results: RNA sequencing analysis of human kidney allograft biopsies during the reperfusion phase showed that the NAD+de novo synthesis is impaired in the immediate post-transplantation period, whereas the salvage pathway is stimulated. This decrease in de novo NAD+ synthesis was confirmed in two mouse models of IRI where NR supplementation prevented plasma urea and creatinine elevation and tubular injury. In human biopsies from CKD patients, the NAD+de novo synthesis pathway was impaired according to CKD stage, with better preservation of the salvage pathway. Similar alterations in gene expression were observed in mice with UUO or chronic proteinuric glomerular disease. NR supplementation did not prevent CKD progression, in contrast to its efficacy in AKI., Conclusion: Impairment of NAD+ synthesis is a hallmark of AKI and CKD. NR supplementation is beneficial in ischaemic AKI but not in CKD models., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. Kinetic GFR Outperforms CKD-EPI for Slow Graft Function Prediction in the Immediate Postoperative Period Following Kidney Transplantation.
- Author
-
Dash J, Verissimo T, Faivre A, Berchtold L, Berney T, Pugin J, de Seigneux S, and Legouis D
- Abstract
Background: Rapid identification of patients at high risk for slow graft function (SGF) is of major importance in the immediate period following renal graft transplantation, both for early therapeutic decisions and long-term prognosis. Due to the high variability of serum creatinine levels after surgery, glomerular filtration rate (GFR) estimation is challenging. In this situation, kinetic estimated GFR (KeGFR) equations are interesting tools but have never been assessed for the identification of SGF patients., Methods: We conducted a single-center retrospective cohort study, including all consecutive kidney allograft recipients in the University Hospitals of Geneva from 2008 to 2016. GFR was estimated using both CKD-EPI and KeGFR formulae. Their accuracies for SGF prediction were compared. Patients were followed up for one year after transplantation., Results: A total of 326 kidney recipients were analyzed. SGF occurred in 76 (23%) patients. KeGFR estimation stabilized from the day following kidney transplantation, more rapidly than CKD-EPI. Discrimination ability for SGF prediction was better for KeGFR than CKD-EPI (AUC 0.82 and 0.66, p < 0.001, respectively)., Conclusion: KeGFR computed from the first day after renal transplantation was able to predict SGF with good discrimination, outperforming CKD-EPI estimation. SGF patients had lower renal graft function overall at the one-year follow up.
- Published
- 2020
- Full Text
- View/download PDF
43. Exploring blood alterations in chronic kidney disease and haemodialysis using metabolomics.
- Author
-
Gagnebin Y, Jaques DA, Rudaz S, de Seigneux S, Boccard J, and Ponte B
- Subjects
- Aged, Biomarkers blood, Case-Control Studies, Chromatography, Liquid methods, Cross-Sectional Studies, Female, Humans, Kidney physiopathology, Male, Metabolome, Middle Aged, Renal Dialysis, Renal Insufficiency, Chronic therapy, Spectrometry, Mass, Electrospray Ionization methods, Tertiary Care Centers, Metabolomics methods, Renal Insufficiency, Chronic blood
- Abstract
Chronic kidney disease (CKD) is characterized by retention of uremic solutes. Compared to patients with non-dialysis dependent CKD, those requiring haemodialysis (HD) have increased morbidity and mortality. We wished to characterise metabolic patterns in CKD compared to HD patients using metabolomics. Prevalent non-HD CKD KDIGO stage 3b-4 and stage 5 HD outpatients were screened at a single tertiary hospital. Various liquid chromatography approaches hyphenated with mass spectrometry were used to identify 278 metabolites. Unsupervised and supervised data analyses were conducted to characterize metabolic patterns. 69 patients were included in the CKD group and 35 in the HD group. Unsupervised data analysis showed clear clustering of CKD, pre-dialysis (preHD) and post-dialysis (postHD) patients. Supervised data analysis revealed qualitative as well as quantitative differences in individual metabolites profiles between CKD, preHD and postHD states. An original metabolomics framework could discriminate between CKD stages and highlight HD effect based on 278 identified metabolites. Significant differences in metabolic patterns between CKD and HD patients were found overall as well as for specific metabolites. Those findings could explain clinical discrepancies between patients requiring HD and those with earlier stage of CKD.
- Published
- 2020
- Full Text
- View/download PDF
44. Diffusion magnetic resonance imaging detects an increase in interstitial fibrosis earlier than the decline of renal function.
- Author
-
Berchtold L, Crowe LA, Friedli I, Legouis D, Moll S, de Perrot T, Martin PY, Vallée JP, and de Seigneux S
- Published
- 2020
- Full Text
- View/download PDF
45. Validation of the corticomedullary difference in magnetic resonance imaging-derived apparent diffusion coefficient for kidney fibrosis detection: a cross-sectional study.
- Author
-
Berchtold L, Friedli I, Crowe LA, Martinez C, Moll S, Hadaya K, de Perrot T, Combescure C, Martin PY, Vallée JP, and de Seigneux S
- Subjects
- Cross-Sectional Studies, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Pilot Projects, ROC Curve, Diffusion Magnetic Resonance Imaging methods, Fibrosis diagnosis, Kidney Cortex pathology, Kidney Diseases diagnosis, Kidney Medulla pathology
- Abstract
Background: Kidney cortical interstitial fibrosis (IF) is highly predictive of renal prognosis and is currently assessed by the evaluation of a biopsy. Diffusion magnetic resonance imaging (MRI) is a promising tool to evaluate kidney fibrosis via the apparent diffusion coefficient (ADC), but suffers from inter-individual variability. We recently applied a novel MRI protocol to allow calculation of the corticomedullary ADC difference (ΔADC). We here present the validation of ΔADC for fibrosis assessment in a cohort of 164 patients undergoing biopsy and compare it with estimated glomerular filtration rate (eGFR) and other plasmatic parameters for the detection of fibrosis., Methods: This monocentric cross-sectional study included 164 patients undergoing renal biopsy at the Nephrology Department of the University Hospital of Geneva between October 2014 and May 2018. Patients underwent diffusion-weighted imaging, and T1 and T2 mappings, within 1 week after biopsy. MRI results were compared with gold standard histology for fibrosis assessment., Results: Absolute cortical ADC or cortical T1 values correlated poorly to IF assessed by the biopsy, whereas ΔADC was highly correlated to IF (r=-0.52, P < 0.001) and eGFR (r = 0.37, P < 0.01), in both native and allograft patients. ΔT1 displayed a lower, but significant, correlation to IF and eGFR, whereas T2 did not correlate to IF nor to eGFR. ΔADC, ΔT1 and eGFR were independently associated with kidney fibrosis, and their combination allowed detection of extensive fibrosis with good specificity., Conclusion: ΔADC is better correlated to IF than absolute cortical or medullary ADC values. ΔADC, ΔT1 and eGFR are independently associated to IF and allow the identification of patients with extensive IF., (© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
46. Impact of superimposed nephrological care to guidelines-directed management by primary care physicians of patients with stable chronic kidney disease: a randomized controlled trial.
- Author
-
Saudan P, Ponte B, Marangon N, Martinez C, Berchtold L, Jaques D, Ernandez T, de Seigneux S, Carballo S, Perneger T, and Martin PY
- Subjects
- Disease Progression, Female, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Patient Acuity, Physicians, Primary Care, Practice Guidelines as Topic, Prognosis, Standard of Care organization & administration, Interdisciplinary Communication, Nephrology methods, Patient Care Management methods, Patient Care Management organization & administration, Primary Health Care methods, Referral and Consultation organization & administration, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic therapy
- Abstract
Background: Optimal clinical care of patients with chronic kidney disease (CKD) requires collaboration between primary care physicians (PCPs) and nephrologists. We undertook a randomised trial to determine the impact of superimposed nephrologist care compared to guidelines-directed management by PCPs in CKD patients after hospital discharge., Methods: Stage 3b-4 CKD patients were enrolled during a hospitalization and randomised in two arms: Co-management by PCPs and nephrologists (interventional arm) versus management by PCPs with written instructions and consultations by nephrologists on demand (standard care). Our primary outcome was death or rehospitalisation within the 2 years post-randomisation. Secondary outcomes were: urgent renal replacement therapy (RRT), decline of renal function and decrease of quality of life at 2 years., Results: From November 2009 to the end of June 2013, we randomised 242 patients. Mean follow-up was 51 + 20 months. Survival without rehospitalisation, GFR decline and elective dialysis initiation did not differ between the two arms. Quality of life was also similar in both groups. Compared to randomised patients, those who either declined to participate in the study or were previously known by nephrologists had a worse survival., Conclusion: These results do not demonstrate a benefit of a regular renal care compared to guided PCPs care in terms of survival or dialysis initiation in CKD patients. Increased awareness of renal disease management among PCPs may be as effective as a co-management by PCPs and nephrologists in order to improve the prognosis of moderate-to-severe CKD., Trial Registration: This study was registered on June 29, 2009 in clinicaltrials.gov (NCT00929760) and adheres to CONSORT 2010 guidelines.
- Published
- 2020
- Full Text
- View/download PDF
47. Renal injury and human immunodeficiency virus: what remains after 30 years?
- Author
-
de Seigneux S and Lucas GM
- Subjects
- HIV, Humans, Kidney, Prevalence, HIV Infections
- Published
- 2020
- Full Text
- View/download PDF
48. Case report: a 58 -year -old man with small kidneys and elevated liver enzymes.
- Author
-
Dash J, Saudan P, Paoloni-Giacobino A, Moll S, and de Seigneux S
- Subjects
- Codon, Nonsense, Diagnosis, Differential, Disease Progression, Humans, Kidney Function Tests, Kidney Transplantation methods, Male, Middle Aged, Organ Size, Peritoneal Dialysis methods, Sequence Deletion, Endodeoxyribonucleases genetics, Exodeoxyribonucleases genetics, Kidney diagnostic imaging, Kidney pathology, Liver diagnostic imaging, Liver pathology, Liver Function Tests methods, Multifunctional Enzymes genetics, Nephritis, Interstitial diagnosis, Nephritis, Interstitial genetics, Nephritis, Interstitial physiopathology, Nephritis, Interstitial therapy, Respiratory Tract Infections diagnosis, Respiratory Tract Infections etiology
- Abstract
Background: The conjunction of hepatitis and renal disease can be seen in several clinical context, including karyomegalic nephritis (KIN). Karyomegalic nephritis (KIN) is a rare genetic disease, with less than 50 cases reported, which incidence is probably underestimated. We report here an unusual case presentation of KIN with obtention of several organ biopsies and a novel mutation leading to the disease., Case Presentation: A 58 year old Caucasian without relevant family history presents with advanced chronic kidney disease, elevated liver enzymes and recurrent pulmonary infection. Familial history was negative. Renal biopsy revealed a chronic tubulo-intertsitial nephritis with enlarged and irregular hyperchromatic nuclei. Karyomegalic nephritis (KIN) was confirmed by genetic testing with a non-sense mutation and a deletion in the Fanconi anemia associated nuclease 1 (FAN1) gene., Conclusions: KIN is rare disease to be suspected in the presence of renal disease, biological hepatitis and recurrent pulmonary infections, even without a familial history. Diagnosis of this condition is crucial to perform family screening, avoid progression factors, and adapt post transplantation immunosuppression. Finally, avoiding familial heterozygote donors appears of major importance in this condition.
- Published
- 2020
- Full Text
- View/download PDF
49. Dialysis initiation improves calcification propensity.
- Author
-
Ponte B, Pruijm M, Pasch A, Dufey-Teso A, Martin PY, and de Seigneux S
- Subjects
- Aged, C-Reactive Protein metabolism, Calcinosis blood, Female, Humans, Magnesium blood, Male, Middle Aged, Phosphates blood, Prospective Studies, Calcification, Physiologic physiology, Calcinosis prevention & control, Kidney Failure, Chronic therapy, Renal Dialysis methods
- Abstract
Background: Cardiovascular morbidity and mortality is high in patients starting dialysis and could be related to modifications of calcification inducers and inhibitors by dialysis, promoting cardiovascular events. The impact of dialysis initiation on serum calcification propensity evolution and arterial stiffness is unknown. We therefore prospectively determined the evolution of the one-half maximal transition time (T50) value and its main determinants as well as pulse wave velocity over the first 3 months of dialysis initiation., Methods: We analysed the evolution of T50, fetuin-A and mineral metabolism parameters before dialysis initiation (M0) and monthly until Month 3 (M3) in incident patients starting haemodialysis (HD) or peritoneal dialysis (PD) in two tertiary Swiss university hospitals. Arterial stiffness was assessed by pulse tonometry at M0 and M3 and biological parameters were compared between M0 and M3 and before/after HD. Linear mixed models were used to assess parameter evolution over time, taking into account repeated measures and other influencing variables., Results: Forty-six patients on HD and 12 on PD were followed. Among them, 45 were male (78%) with a median age of 67 years (25th-75th quartile range 54-77). T50 significantly increased between M0 and M3 from 183 (120-266) to 246 min (175-330) (P < 0.001). Fetuin-A, calcium and magnesium also increased while phosphate decreased. Factors associated with T50 changes over time were fetuin-A, phosphate and magnesium (P < 0.001). Fetuin-A changes were associated with inflammation-related factors (albumin, C-reactive protein) but not calcium and phosphate levels. Arterial stiffness was not significantly modified over 3 months. PD and HD initiation showed similar trends., Conclusions: Dialysis initiation significantly improves calcification propensity and fetuin-A levels. These modifications do not explain the high mortality related to dialysis initiation. The clinical relevance of using T50 values to initiate dialysis awaits further studies., (© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
50. The KNOW-CKD study: evidence for a link between proteinuria and alterations of mineral metabolism.
- Author
-
de Seigneux S, Delitsikou V, and Martin PY
- Subjects
- Cohort Studies, Fibroblast Growth Factor-23, Fibroblast Growth Factors, Humans, Minerals, Phosphates, Proteinuria, Republic of Korea, Renal Insufficiency, Chronic
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.